Clinical trials: End-Stage Heart Failure
End-Stage Renal Disease, Hemodialysis
Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry
The high rate of cardiovascular complications in the dialysis population cannot be explained by traditional cardiovascular risk factors.
- Trial name
- NCT00297219
- Testing
- Low dialysate calcium, high dialysate calcium
- Where
- 3 sites in United States, Turkey (Türkiye)
- Volunteers
- 457 people
- Sponsor
- Ege University
Breast Neoplasms, Heart Failure
Cardiotoxicity of Adjuvant Trastuzumab
Trastuzumab (Herceptin®) increases the chances of cure in patients with Her-2 overexpressing early breast cancer. Unfortunately, both the chemotherapy drugs used in this setting (anthracyclines) and trastuzumab are known to cause…
- Trial name
- CATS (NCT00858039)
- Where
- 15 sites in Australia
- Volunteers
- 220 people
- Sponsor
- Royal Prince Alfred Hospital, Sydney, Australia
End-stage Renal Disease
Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD)
The purpose of the study is to investigate whether oral sodium bicarbonate supplementation to ensure a constant bicarbonate profile in haemodialysis patients will primarily lower predialysis potassium levels and secondary lead to…
- Trial name
- BicHD (NCT02692378)
- Testing
- sodium bicarbonate 500mg capsules
- Where
- United Kingdom
- Volunteers
- 44 people
- Sponsor
- Imperial College Healthcare NHS Trust
Liver Transplant; Complications, Ischemia Reperfusion Injury
Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation
The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation.
- Conditions
- Liver Transplant; Complications, Ischemia Reperfusion Injury, Cirrhosis, Liver Cancer
- Trial name
- NCT03946852
- Testing
- Abdominal Regional Perfusion
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre
Myocardial Stunning, End-stage Renal Disease
Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration
Chronic kidney disease (CKD) is linked to elevated mortality rate, and cardiovascular disease is the main cause related to this outcome.
- Trial name
- NCT02545426
- Testing
- Change the dialysate calcium concentration
- Where
- Brazil
- Volunteers
- 19 people
- Sponsor
- University of Sao Paulo General Hospital
Heart Failure, Heart Transplantation
Medical Care Versus Ventricular Assist Device for the Management of End-stage Heart Failure (MEVADE)
End-stage heart failure (ESHF) represents a major burden in terms of quality of life, mortality and costs. The current practice in France is to treat patients with ESHF by a combination of drugs and lifestyle interventions before…
- Conditions
- Heart Failure, Heart Transplantation, Heart-Assist Devices
- Trial name
- MEVADE (NCT03105726)
- Volunteers
- 224 people
- Sponsor
- Joe Elie Salem
Heart Failure, Ventricular Dysfunction, Left
Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone
The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic…
- Trial name
- NCT00391846
- Testing
- Captopril, Enalapril, Lisinopril
- Where
- 39 sites in Sweden
- Volunteers
- 252 people
- Sponsor
- AstraZeneca
Complication of Hemodialysis, Cardiovascular Diseases
Sodium Thiosulfate Treatment of Vascular Calcification in ESRD
Cardiovascular disease is the major cause of death in the hemodialysis population and calcification of the major arteries (coronary, aorta, and carotid) are a play a central role in this process.
- Trial name
- NCT00568399
- Testing
- sodium thiosulfate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
End-stage Heart Failure
Echocardiographic Assessment of the Effect of Impella on Biventricular Function
The objective of this prospective observational study is to evaluate the effects of Impella 5.5 on biventricular function in adult patients with end-stage heart failure requiring temporary mechanical circulatory support.
- Trial name
- NCT07534462
- Testing
- Echocardiographic Assessment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Rochester
Coronary Artery Disease, Acute Liver Failure
Cardiac Risk Assessment Using Standard of Care Versus CTA and Heart Flow FFRct
Coronary Artery Disease (CAD) is the narrowing or blockage of the artery of the heart and is prevalent in end-stage liver disease.
- Conditions
- Coronary Artery Disease, Acute Liver Failure, Liver Transplant
- Trial name
- CRASCH-Liver (NCT04089969)
- Testing
- CTA/FFRct, SOC cardiovascular evaluation
- Sponsor
- Corewell Health East
End-stage Renal Disease
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
Primary Objective: To investigate the efficacy of the standard dose of Thymoglobuline® induction therapy for preventing acute rejection (AR) after transplantation among recipients of Donated after Cardiac Death (DCD) kidney…
- Trial name
- START-DCD (NCT03099122)
- Testing
- Rabbit Anti-thymocyte Immunoglobulin, Tacrolimus, Methylprednisolone
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Sanofi
Heart Failure, Hyperuricemia
Long-term Prednisone Use for End-stage Heart Failure
Patients with advanced (ACCF/AHA stage D) heart failure and hyperuricemia have high one-year mortality. Currently, there was no evidence-based therapy such as mechanically assisted circulatory support available in China.
- Trial name
- NCT02282683
- Testing
- prednisone
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hebei Medical University
End Stage Renal Failure
Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients
Hyperphosphatemia and elevated cardiac biomarkers are two key characteristics of patients in end stage renal diseases(ESRD),however the majority of whom are in the absence of acute coronary syndrome(ACS).
- Trial name
- NCT01781156
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai 10th People's Hospital
Heart Failure, End-stage Disease
Proactive Palliative Care for Patients With Ventricular Assist Devices (VAD) and Their Families
The primary aim of the study is to provide "proof of concept" to demonstrate that patients with Ventricular Assist Devices (VADs) and caregivers are willing to be enrolled in a randomized trial of palliative care and that such a…
- Trial name
- NCT01427634
- Testing
- Palliative Care, Usual Care
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Dialysis, Chronic Kidney Disease (Stages 3b-5)
Left Atrial Appendage Occlusion in Dialysis Patients With Atrial Fibrillation: A Multicentre Pilot Study
Objectives: This pilot study aims to evaluate the safety and efficacy of left atrial appendage occlusion (LAAO) in dialysis patients and atrial fibrillation (AF) to establish a novel stroke prevention strategy and determine an…
- Conditions
- Dialysis, Chronic Kidney Disease (Stages 3b-5), Atrial Fibrillation, End Stage Kidney Failure
- Trial name
- LAAO-DAF (NCT07257614)
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
End Stage Kidney Disease
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This is a two-part, phase 2b and phase 3 combined prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1: Phase 2b is a dose-finding study for CSL300 vs placebo.
- Trial name
- POSIBIL6ESKD (NCT05485961)
- Testing
- CSL300
- Where
- 566 sites in United States, Argentina and 33 more
- Volunteers
- 3,110 people
- Sponsor
- CSL Behring
End-stage Heart Failure
Cardiac Mitochondrial Function in Explanted Human Hearts
Background: Treatment of heart failure has improved considerably in the past decades. Despite this improvement, the disease may progress into an end-stage ultimately leaving the physicians with no other treatment option than…
- Trial name
- NCT04500938
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Whole Heart Radiotherapy for End-stage Heart Failure
End-stage heart failure (ESHF) causes recurrent hospitalizations, cardiac arrhythmias, and intolerance to standard HF therapies are common as the disease progresses.
- Conditions
- Heart Failure NYHA Class III, Heart Failure NYHA Class IV, End-stage Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- ESHF-WHRT (NCT06299176)
- Testing
- Whole Heart Radiation Therapy
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre